Exelixis Inc., of South San Francisco, reported top-line results from the final analysis of COMET-2, its randomized, double-blind, controlled trial of cabozantinib in men with metastatic castration-resistant prostate cancer (mCRPC) who are suffering from moderate to severe pain despite optimized narcotic medication, and whose disease has progressed following treatment with docetaxel as well as Zytiga (abiraterone, Johnson & Johnson) and/or Xtandi (enzalutamide, Medivation Inc. and Astellas Pharma Inc.).